Literature DB >> 33439423

Prophylactic antiemetic effects of dexamethasone versus 5-HT3 receptor antagonists in ear surgery: a systematic review and meta-analysis.

Hsin-Ming Liu1,2, Jin-Hua Chen3,4,5, Chiehfeng Chen2,6,7,8,9, Cher-Ming Liou10.   

Abstract

Background The optimal strategy for reducing the high incidence of postoperative nausea and vomiting (PONV) after otologic surgical procedures remains inconclusive. Aim of the review This study compared the prophylactic antiemetic effects of dexamethasone with 5-hydroxytryptamine 3 receptor antagonists (5-HT3-RAs) in ear surgery. Method PubMed, Embase, and Cochrane Library were searched up to October 31, 2020 for randomized controlled trials that used dexamethasone either singly or in combination with 5-HT3-RAs for PONV prophylaxis in adults undergoing ear surgery. Studies in languages other than English and those without a control group of 5-HT3-RAs were excluded. Random effects meta-analyses were performed, and risk of bias was assessed using the version 2 of the Cochrane risk-of-bias tool. Main outcome measures include incidences of early (< 6 h) and overall (0-48 h) PONV, the overall requirement for rescue antiemetics, and the occurrence of adverse events. Results Eight trials of 733 adults were included, and the overall risks of bias were generally low. Pooled risk ratios (RRs) of early and overall PONV of dexamethasone versus 5-HT3-RAs were 2.0 (95% CI 0.8-5.1, I2 = 82%), and 1.3 (95% CI 0.6-2.6, I2 = 86%). In studies comparing dexamethasone plus 5-HT3-RAs with 5-HT3-RAs alone, pooled RRs of early and overall PONV were 0.8 (95% CI 0.4-1.4, I2 = 30%), and 0.5 (95% CI 0.3-0.6, I2 = 0%), respectively. Pooled RRs of the overall need for rescue antiemetics comparing 5-HT3-RAs with dexamethasone alone and in combination with 5-HT3-RAs were 1.2 (95% CI 0.4-3.9, I2 = 73%) and 0.4 (95% CI 0.1-1.4, I2 = 61%), respectively. Common adverse events reported were headache and dizziness, and the incidences range from 0 to 10% without significant differences between the groups. Conclusion The prophylactic antiemetic effects of dexamethasone versus 5-HT3-RAs in ear surgery did not significantly differ in the early and overall postoperative phases. The combination of dexamethasone with 5-HT3-RAs showed superior overall PONV prophylactic effects to 5-HT3-RAs alone in ear surgery, but their differences in the need for rescue antiemetics remained non-significant.

Entities:  

Keywords:  5-Hydroxytryptamine receptor antagonist; Antiemetic; Dexamethasone; Ear surgery; Postoperative nausea and vomiting

Year:  2021        PMID: 33439423     DOI: 10.1007/s11096-020-01227-6

Source DB:  PubMed          Journal:  Int J Clin Pharm


  19 in total

1.  Antiemetic effects of granisetron, droperidol and dexamethasone in otologic surgery.

Authors:  Sitki Goksu; Hasan Kocoglu; Yildirim A Bayazit; Sahin Yüksek; Yasemin Karci; Muzaffer Kanlikama; Unsal Oner
Journal:  Auris Nasus Larynx       Date:  2002-07       Impact factor: 1.863

Review 2.  Perioperative antiemetic efficacy of dexamethasone versus 5-HT3 receptor antagonists: a meta-analysis and trial sequential analysis of randomized controlled trials.

Authors:  Preet Mohinder Singh; Anuradha Borle; Rajesh Panwar; Jeetinder Kaur Makkar; Ian McGrath; Anjan Trikha; Ashish Sinha
Journal:  Eur J Clin Pharmacol       Date:  2018-06-01       Impact factor: 2.953

3.  Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review.

Authors:  I Henzi; B Walder; M R Tramèr
Journal:  Anesth Analg       Date:  2000-01       Impact factor: 5.108

4.  Prevention of nausea and vomiting after middle ear surgery: combination of ondansetron and dexamethasone is the right choice.

Authors:  Nidhi Bidyut Panda; Neerja Bharadwaj; Puneet Kapoor; Pramila Chari; Naresh K Panda
Journal:  J Otolaryngol       Date:  2004-04

5.  Low-dose dexamethasone reduces nausea and vomiting after tympanomastoid surgery: a comparison of tropisetron with saline.

Authors:  Jhi-Joung Wang; Pa-Chun Wang; Yun-Hou Liu; Chih-Cheng Chien
Journal:  Am J Otolaryngol       Date:  2002 Sep-Oct       Impact factor: 1.808

Review 6.  Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting.

Authors:  Tong J Gan; Kumar G Belani; Sergio Bergese; Frances Chung; Pierre Diemunsch; Ashraf S Habib; Zhaosheng Jin; Anthony L Kovac; Tricia A Meyer; Richard D Urman; Christian C Apfel; Sabry Ayad; Linda Beagley; Keith Candiotti; Marina Englesakis; Traci L Hedrick; Peter Kranke; Samuel Lee; Daniel Lipman; Harold S Minkowitz; John Morton; Beverly K Philip
Journal:  Anesth Analg       Date:  2020-08       Impact factor: 5.108

7.  A factorial trial of six interventions for the prevention of postoperative nausea and vomiting.

Authors:  Christian C Apfel; Kari Korttila; Mona Abdalla; Heinz Kerger; Alparslan Turan; Ina Vedder; Carmen Zernak; Klaus Danner; Ritva Jokela; Stuart J Pocock; Stefan Trenkler; Markus Kredel; Andreas Biedler; Daniel I Sessler; Norbert Roewer
Journal:  N Engl J Med       Date:  2004-06-10       Impact factor: 91.245

8.  Comparison of the antiemetic effect of ramosetron with the combination of dexamethasone and ondansetron in middle ear surgery: A double-blind, randomized clinical study.

Authors:  Sameer Desai; M C B Santosh; Rashmi Annigeri; V B Santoshi; Raghavendra Rao
Journal:  Saudi J Anaesth       Date:  2013-07

9.  A randomized study to compare palonosetron with ondansetron for prevention of postoperative nausea and vomiting following middle ear surgeries.

Authors:  Shubhangi Sharma; Sangeeta Khanna; Jyotirmoy Das; Yatin Mehta; Kumud Kumar Handa
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2019 Apr-Jun

10.  A comparison of preoperative ondansetron and dexamethasone in the prevention of post-tympanoplasty nausea and vomiting.

Authors:  Mahmoud Eidi; Khosro Kolahdouzan; Hamzeh Hosseinzadeh; Razieh Tabaqi
Journal:  Iran J Med Sci       Date:  2012-09
View more
  1 in total

1.  Effect of ondansetron for preventing postoperative nausea and vomiting after breast cancer surgery.

Authors:  Chunlei Li; Wenbin Cui; Panpan Song; Wang Liu; Xiaodong Wang; Qiang Yang
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.